Gefitinib in heavily pretreated non small cell lung cancer: Results of the expanded access program in Eastern France.

被引：0
|
作者：
Spaeth, D
Deplanque, G
Favrot, N
Paillot, N
Lang, MP
Cuguiliere, A
Seigneur, J
机构：
[1] Ctr Alexis Vautrin, Nancy, France
[2] Dept Oncol, Scy Chazelles, France
[3] Ctr GF Leclerc, Dijon, France
[4] Serv Pneumol, Metz, France
[5] Serv Pneumol, Mt St Martin, France
[6] HIA Legouest, Metz, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7323
引用
收藏
页码：696S / 696S
页数：1
相关论文
共 50 条
  • [31] Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a US expanded access program (EAP).
    Ochs, J
    Grous, JJ
    Warner, KL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [32] Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program
    Gridelli, C
    Rossi, A
    Maione, P
    Guerriero, C
    Airoma, G
    Colantuoni, G
    Barzelloni, ML
    ANTICANCER RESEARCH, 2004, 24 (3B) : 1873 - 1877
  • [33] Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer
    Deng, Jing
    Fang, Wei Jia
    Zhang, Xiao Chen
    Wu, Dong Ping
    Fang, Hong Ming
    Chen, Jing
    Qian, Jiong
    Mou, Hai Bo
    Chu, Bin Bin
    Xu, Nong
    Teng, Li Song
    MEDICAL ONCOLOGY, 2012, 29 (02) : 595 - 599
  • [34] Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer
    Jing Deng
    Wei Jia Fang
    Xiao Chen Zhang
    Dong Ping Wu
    Hong Ming Fang
    Jing Chen
    Jiong Qian
    Hai Bo Mou
    Bin Bin Chu
    Nong Xu
    Li Song Teng
    Medical Oncology, 2012, 29 : 595 - 599
  • [35] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Cappuzzo, F
    Bartolini, S
    Ceresoli, GL
    Tamberi, S
    Spreafico, A
    Lombardo, L
    Gregorc, V
    Toschi, L
    Calandri, C
    Villa, E
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 82 - 86
  • [36] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    F Cappuzzo
    S Bartolini
    G L Ceresoli
    S Tamberi
    A Spreafico
    L Lombardo
    V Gregorc
    L Toschi
    C Calandri
    E Villa
    L Crinò
    British Journal of Cancer, 2004, 90 : 82 - 86
  • [37] Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
    Crino, Lucio
    Bidoli, Paolo
    Delmonte, Angelo
    Grossi, Francesco
    De Marinis, Filippo
    Ardizzoni, Andrea
    Vitiello, Fabiana
    Lo Russo, Giuseppe
    Parra, Hector Soto
    Cortesi, Enrico
    Cappuzzo, Federico
    Calabro, Luana
    Tiseo, Marcello
    Turci, Daniele
    Gamucci, Teresa
    Antonelli, Paola
    Morabito, Alessandro
    Chella, Antonio
    Giannarelli, Diana
    Galetta, Domenico
    ONCOLOGIST, 2019, 24 (11): : E1165 - E1171
  • [38] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Dongiovanni, Vincenzo
    Dongiovanni, Diego
    Buffoni, Lucio
    Barone, Carla
    Fissore, Camilla
    Addeo, Alfredo
    Larovere, Erika
    Grillo, Raffaella
    Nuzzolo, Gloria
    Schena, Marina
    Bertetto, Oscar
    ANNALS OF ONCOLOGY, 2005, 16 : 21 - 22
  • [39] Gefitinib for the treatment of non-small-cell lung cancer
    Campbell, Lynn
    Blackhall, Fiona
    Thatcher, Nicholas
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1343 - 1357
  • [40] Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer
    Yusuf, Syed W.
    Kim, Peter
    Durand, Jean-Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (24): : 2367 - 2367
12345